References
Pagnoux C, Guilpain P, Guillevin L (2007) Churg-Strauss syndrome. Curr Opin Rheumatol 19:25–32. doi:10.1097/BOR.0b013e3280119854
Phillips LHII (2003) The epidemiology of myasthenia gravis. Ann NY Acad Sci 998:407–412. doi:10.1196/annals.1254.053
Davis MDP, Daoud MS, McEvoy MT, Su WPD (1997) Cutaneous manifestations of Churg-Strauss syndrome: a clinicopathologic correlation. J Am Acad Dermatol 37:199–203. doi:10.1016/S0190-9622(97)80125-9
Thomas-Golbanov C, Sridharan S (2001) Novel therapies in vasculitis. Expert Opin Investig Drugs 10:1279–1289. doi:10.1517/13543784.10.7.1279
Boumpas DT, Kritikos HD, Daskalakis NG (2002) Perspective of future therapy of vasculitis. Curr Rheumatol Rep 2:423. doi:10.1007/s11926-000-0043-5
Sloper CM, Powell RJ, Dua HS (1999) Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology 106:723–728. doi:10.1016/S0161-6420(99)90156-2
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Niiyama, S., Amoh, Y., Suzuki, K. et al. Efficacy of tacrolimus against Churg-Strauss syndrome in a patient with myasthenia gravis. Rheumatol Int 30, 847–848 (2010). https://doi.org/10.1007/s00296-009-1039-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-009-1039-8